CL2018000357A1 - Polipéptidos mrka, anticuerpos y usos los mismos - Google Patents

Polipéptidos mrka, anticuerpos y usos los mismos

Info

Publication number
CL2018000357A1
CL2018000357A1 CL2018000357A CL2018000357A CL2018000357A1 CL 2018000357 A1 CL2018000357 A1 CL 2018000357A1 CL 2018000357 A CL2018000357 A CL 2018000357A CL 2018000357 A CL2018000357 A CL 2018000357A CL 2018000357 A1 CL2018000357 A1 CL 2018000357A1
Authority
CL
Chile
Prior art keywords
klebsiella
antibodies
mrka
fragments
same
Prior art date
Application number
CL2018000357A
Other languages
English (en)
Inventor
Qun Wang
Saravanan RAJAN
Chew-Shun Chang
Thompson Jenny Heidbrink
Hung-Yu Lin
Charles Kendall Stover
Meghan Pennini
William Dall'acqua
Partha S Chowdhury
Xiaodong Xiao
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of CL2018000357A1 publication Critical patent/CL2018000357A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

<p>LA PRESENTE DIVULGACIÓN PROPORCIONA PROTEÍNAS DE UNIÓN A MRKA, P.EJ., ANTICUERPOS O FRAGMENTOS DE UNIÓN A ANTÍGENO DE LOS MISMOS QUE SE UNEN A MRKA E INDUCEN LA DESTRUCCIÓN OPSONOFAGOCÍTICA DE KLEBSIELLA (P. EJ., KLEBSIELLA PNEUMONIAE). LA PRESENTE DIVULGACIÓN TAMBIÉN PROPORCIONA MÉTODOS DE REDUCCIÓN DE KLEBSIELLA (P. EJ., KLEBSIELLA PNEUMONIAE) O TRATAMIENTO O PREVENCIÓN DE INFECCIÓN POR KLEBSIELLA (P. EJ., KLEBSIELLA PNEUMONIAE) EN UN SUJETO, QUE COMPRENDEN ADMINISTRAR PROTEÍNAS DE UNIÓN A MRKA, P. EJ., ANTICUERPOS O FRAGMENTOS DE UNIÓN A ANTÍGENO DE LOS MISMOS, POLIPÉPTIDOS MRKA, FRAGMENTOS INMUNÓGENOS DE LOS MISMOS, O POLINUCLEÓTIDOS QUE CODIFICAN MRKA O FRAGMENTOS INMUNÓGENOS DE LOS MISMOS AL SUJETO.</p>
CL2018000357A 2015-08-24 2018-02-08 Polipéptidos mrka, anticuerpos y usos los mismos CL2018000357A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562208975P 2015-08-24 2015-08-24
US201562238828P 2015-10-08 2015-10-08

Publications (1)

Publication Number Publication Date
CL2018000357A1 true CL2018000357A1 (es) 2018-07-20

Family

ID=58100831

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000357A CL2018000357A1 (es) 2015-08-24 2018-02-08 Polipéptidos mrka, anticuerpos y usos los mismos

Country Status (16)

Country Link
US (2) US20170073397A1 (es)
EP (1) EP3341004A4 (es)
JP (1) JP2018527924A (es)
KR (1) KR20180042300A (es)
CN (1) CN107921086A (es)
AU (1) AU2016313653A1 (es)
BR (1) BR112018003252A2 (es)
CA (1) CA2995387A1 (es)
CL (1) CL2018000357A1 (es)
CO (1) CO2018001985A2 (es)
HK (1) HK1252350A1 (es)
IL (1) IL257434A (es)
MX (1) MX2018001964A (es)
RU (1) RU2018107056A (es)
TW (1) TW201718626A (es)
WO (1) WO2017035154A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900027XA (en) * 2016-08-05 2019-02-27 Medimmune Llc Anti-o2 antibodies and uses thereof
JP7160484B2 (ja) 2016-10-19 2022-10-25 メディミューン，エルエルシー 抗ｏ１抗体およびその使用
EP3641828B1 (en) * 2017-06-23 2023-11-22 Affinivax, Inc. Immunogenic compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7041465B1 (en) * 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
WO2001010386A2 (en) * 1999-08-11 2001-02-15 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
AU2004279441B2 (en) * 2003-10-08 2010-07-01 The Feinstein Institute For Medical Research Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia
CA2654712C (en) * 2006-06-06 2015-05-05 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
EP2497779A1 (en) * 2007-05-02 2012-09-12 Intercell AG Klebsiella antigens
GB0915403D0 (en) * 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
US8961977B2 (en) * 2010-02-12 2015-02-24 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
US20140011691A1 (en) * 2010-10-26 2014-01-09 Arizona Board of Regents, A Body Corporate of the State of Arizona, Acting for and on Behalf of Az. Morphology and protein specific reagents as diagnostics for neurodegenerative diseases
ES2859323T3 (es) * 2011-11-07 2021-10-01 Medimmune Ltd Terapias de combinación que usan moléculas de unión anti-Psl y PcrV de Pseudomonas

Also Published As

Publication number Publication date
RU2018107056A (ru) 2019-09-26
EP3341004A4 (en) 2019-05-15
CA2995387A1 (en) 2017-03-02
MX2018001964A (es) 2018-06-19
AU2016313653A1 (en) 2018-04-12
BR112018003252A2 (pt) 2018-09-25
TW201718626A (zh) 2017-06-01
US20170073397A1 (en) 2017-03-16
KR20180042300A (ko) 2018-04-25
EP3341004A1 (en) 2018-07-04
JP2018527924A (ja) 2018-09-27
US20190062411A1 (en) 2019-02-28
CN107921086A (zh) 2018-04-17
IL257434A (en) 2018-04-30
WO2017035154A1 (en) 2017-03-02
CO2018001985A2 (es) 2018-11-22
HK1252350A1 (zh) 2019-05-24

Similar Documents

Publication Publication Date Title
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
CL2018000744A1 (es) Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso.
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
CL2018000042A1 (es) Anticuerpos de unión a tau
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
SV2018005659A (es) Anticuerpos agonistas que se unen especificamente a cd40 humanos y metodos de uso
EA201892294A1 (ru) Антитела и композиции против tim-3
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
CL2017003427A1 (es) Anticuerpos para cd40
DK3500299T3 (da) Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer
EA201892793A1 (ru) Анти-hla-g специфические антитела
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CU24427B1 (es) Moléculas de anticuerpo que se unen a tim-3
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
CL2018000043A1 (es) Anticuerpos de unión a tau
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
NZ723858A (en) Anti-human ox40l antibodies, uses &amp; methods
CL2019000799A1 (es) Anticuerpos y fragmentos de los mismos que se unen al receptor cannabinoide 1 (cb1) humano. (divisional solicitud 201602433)
DOP2016000334A (es) Anticuerpos antagonistas de interferon alfa y omega
CL2017000912A1 (es) Anticuerpos que se unen a ccr6 y sus usos
MX2018013222A (es) Anticuerpos de interferon beta y usos de los mismos.